For years, a quiet fear has shadowed pregnant women who depend on antidepressants: that in treating their own suffering, they might somehow shape the neurology of the child they carry. A sweeping meta-analysis published in The Lancet Psychiatry, drawing on data from more than 600,000 medicated pregnancies, now offers a measured but meaningful reassurance — the medications themselves are not the cause. What the data reveal instead is the deeper story of inheritance and family circumstance, reminding us that the roots of human development are rarely found in a single variable.
Meta-analysis finds no causal link between pregnancy antidepressants and autism
Cobertura Relacionada
Tras siete años probando móviles plegables, el crítico de El Confidencial analiza el nuevo Samsung Galaxy Z Fold8, un di…
Portal Metropolitano · Aug 25 Delta lanza «Gemini» en Dolby Atmos con show en Club SubterráneoLa banda chilena Delta presenta el lanzamiento de su álbum Gemini en formato Dolby Atmos, posicionándose como pionera de…
Bloomberg Línea · Aug 25 Nvidia enfrenta competencia feroz de clientes y rivales en carrera por chips de IANvidia domina el mercado de chips de IA con 90% de participación, pero enfrenta presión de clientes como Amazon y Google…
El Mundo · Aug 24 Google constituye Waymo Iberia en Madrid a la espera de autorización de la DGT para robotaxisGoogle ha creado Waymo Iberia SL en Madrid como filial para operar coches autónomos en España y Portugal, en espera de a…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
Medical research finding no causal link between pregnancy antidepressants and autism has no geopolitical implications; this is a public health science article.
Lente Econômica
Meta-analysis of 600,000+ pregnancies finds no causal link between common antidepressants and autism/ADHD, reducing liability risks for pharmaceutical companies and potentially increasing medication adherence among pregnant women.
Pregnant women with depression/anxiety gain reassurance to continue antidepressant treatment without fear of causing neurodevelopmental disorders in offspring, improving maternal mental health outcomes and reducing treatment discontinuation.
Regulatory bodies may update pregnancy safety labeling for antidepressants, potentially reducing warning labels and litigation risk. Healthcare systems may expand mental health coverage for pregnant women. Reduced need for expensive autism/ADHD diagnostic testing and interventions if preventable causes are eliminated.